Sagimet Biosciences Inc
For the period ended Dec 31, 2023. Filed Mar 25, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 25, 2024
SGMT$10.83+9.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
(in thousands)
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Year Ended December 31, | ||||||
| · · 2023 · · 2022 | ||||||
| Cash flows from operating activities: · · | ||||||
| Net loss | | $(27,876) | | $(30,499) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | | | ||||
| Accretion of discount on marketable securities, net | | (37) | | (212) | ||
| Non-cash lease expense | | 139 | | 130 | ||
| Stock-based compensation expense | | 4,990 | | 1,880 | ||
| Change in fair value of stock warrant liability | | | (4) | | | (3) |
| Changes in operating assets and liabilities: | | | ||||
| Prepaid expenses and other current assets | | (952) | | 1,436 | ||
| Accounts payable and accrued liabilities | | 120 | | 2,915 | ||
| Operating lease liabilities | | (146) | | (137) | ||
| Net cash used in operating activities | | (23,766) | | (24,490) | ||
| Cash flows from investing activities: | | | ||||
| Purchases of marketable securities | | | (19,620) | | | (41,446) |
| Sales of marketable securities | | 32,200 | | 9,436 | ||
| Net cash provided by (used in) investing activities | | 12,580 | | (32,010) | ||
| Cash flows from financing activities: | | | ||||
| Proceeds from initial public offering, net of underwriters' commissions and discounts | | | 89,679 | | | — |
| Payment of deferred financing costs | | | (3,518) | | | (85) |
| Proceeds from exercise of stock options | | 6 | | 12 | ||
| Net cash provided by (used in) financing activities | | 86,167 | | (73) | ||
| Net increase (decrease) in cash and cash equivalents | | 74,981 | | (56,573) | ||
| Cash and cash equivalents at beginning of period | | 158 | | 56,731 | ||
| Cash and cash equivalents at end of period | | $75,139 | | $158 | ||
| | | | | | | |
| Supplemental non-cash investing and financing activities: | | | | | | |
| Conversion of redeemable convertible preferred stock to Series A and Series B common stock | | $214,620 | | $— | ||
| Reclassification of common stock to Series A common stock | | $1 | | $— | ||
| Deferred financing costs in accrued expenses | | $323 | | $— | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.